Gilead Sciences, Inc. (NASDAQ:GILD) Director Sells $620,355.32 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This represents a 43.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Gilead Sciences Stock Up 0.2 %

Gilead Sciences stock opened at $92.58 on Friday. The firm has a market capitalization of $115.38 billion, a price-to-earnings ratio of 1,028.67, a PEG ratio of 2.87 and a beta of 0.17. The company’s 50 day simple moving average is $88.26 and its 200 day simple moving average is $77.69. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.29 earnings per share. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.37 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be given a $0.77 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.33%. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Institutional Trading of Gilead Sciences

Hedge funds and other institutional investors have recently modified their holdings of the company. CarsonAllaria Wealth Management Ltd. raised its position in Gilead Sciences by 198.3% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 238 shares during the last quarter. nVerses Capital LLC bought a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $25,000. Valued Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares during the last quarter. Cedar Wealth Management LLC boosted its holdings in Gilead Sciences by 51.6% during the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 160 shares during the last quarter. Finally, Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences in the second quarter valued at $33,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Daiwa America raised shares of Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Sanford C. Bernstein began coverage on Gilead Sciences in a research note on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target on the stock. Robert W. Baird increased their price objective on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Cantor Fitzgerald boosted their target price on shares of Gilead Sciences from $70.00 to $80.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Finally, Mizuho increased their target price on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Twelve equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $95.41.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.